Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Locally Advanced HER2-Positive Breast Carcinoma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableNot Yet RecruitingNCT07191405
What this trial is testing

Clinical Study of Chemotherapy and Immunotherapy Combined With Lactobacillus Johnsonii in Patients With Multiple Irresectable Solid Tumors

Who this might be right for
ImmunotherapyChemotherapy
Second Affiliated Hospital, Zhejiang University, School of Medicine 156
Testing effectiveness (Phase 2)Looking for participantsNCT05834764
What this trial is testing

Pyrotinib in Women With High-risk in Early Stage Breast Cancer

Who this might be right for
HER2-positive Breast Cancer
The First Affiliated Hospital with Nanjing Medical University 188
Testing effectiveness (Phase 2)Study completedNCT04836520
What this trial is testing

SHR6390 Combined With Anastrozole for Preoperative Treatment of Breast Cancer.

Who this might be right for
Breast Cancer
Tianjin Medical University Cancer Institute and Hospital 20
Testing effectiveness (Phase 2)Study completedNCT00875979
What this trial is testing

Trastuzumab Emtansine (Trastuzumab-MCC-DM1, T-DM1) in Combination With Pertuzumab Administered to Patients With Human Epidermal Growth Factor Receptor-2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer Who Have Previously Received Trastuzumab

Who this might be right for
Metastatic Breast Cancer
Hoffmann-La Roche 67
Testing effectiveness (Phase 2)Looking for participantsNCT06686394
What this trial is testing

Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)

Who this might be right for
Breast NeoplasmsBreast Cancer
Merck Sharp & Dohme LLC 81
Testing effectiveness (Phase 2)Study completedNCT00826267
What this trial is testing

6 Weeks Treatment of Locally Advanced Breast Cancer With BIBW 2992 (Afatinib) or Lapatinib or Trastuzumab

Who this might be right for
Breast Neoplasms
Boehringer Ingelheim 29
Early research (Phase 1)Study completedNCT03767335
What this trial is testing

MEN1611 With Trastuzumab (+/- Fulvestrant) in Metastatic Breast Cancer

Who this might be right for
Advanced or Metastatic Breast Cancer
Menarini Group 62
Not applicableStudy completedNCT03583463
What this trial is testing

ALEXANDRIA Study Egypt

Who this might be right for
Breast Cancer
AstraZeneca 436
Large-scale testing (Phase 3)Looking for participantsNCT05851014
What this trial is testing

GB491 in Combination With Letrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer

Who this might be right for
Breast Cancer
Genor Biopharma Co., Ltd. 350
Testing effectiveness (Phase 2)Active Not RecruitingNCT02849496
What this trial is testing

Testing Olaparib Either Alone or in Combination With Atezolizumab in BRCA Mutant Non-HER2-positive Breast Cancer

Who this might be right for
Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Locally Advanced Unresectable Breast Carcinoma+1 more
National Cancer Institute (NCI) 89
Testing effectiveness (Phase 2)Ended earlyNCT02067741
What this trial is testing

CR1447 in Endocrine Responsive-HER2neg and TN-ARpos Breast Cancer

Who this might be right for
Metastatic Breast AdenocarcinomaBreast Cancer
Swiss Cancer Institute 29
Large-scale testing (Phase 3)Study completedNCT04629846
What this trial is testing

Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive and Estrogen Receptor/Progesterone Receptor Negative Breast Cancer to Evaluate the Efficiency and Safety of Treatment With Trastuzumab Plus (+) QL1209/Pertuzumab + Docetaxel.

Who this might be right for
Breast Cancer
Qilu Pharmaceutical Co., Ltd. 517
Testing effectiveness (Phase 2)Study completedNCT05963984
What this trial is testing

Samuraciclib in Combination With Fulvestrant in Metastatic or Locally Advanced Breast Cancer in Adult Participants

Who this might be right for
Metastatic Breast CancerLocally Advanced Breast CancerBreast Cancer
Carrick Therapeutics Limited 60
Large-scale testing (Phase 3)Study completedNCT03262935
What this trial is testing

SYD985 vs. Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Byondis B.V. 437
Testing effectiveness (Phase 2)Study completedNCT02954055
What this trial is testing

MEtronomic TrEatment Option in Advanced bReast cAncer

Who this might be right for
Breast Cancer
ETOP IBCSG Partners Foundation 140
Large-scale testing (Phase 3)Looking for participantsNCT07797218
What this trial is testing

Neoadjuvant Pyrotinib-to-pertuzumab in HER2+ eBC

Who this might be right for
Breast Cancer Early Stage Breast Cancer (Stage 1-3)
Shanghai Jiao Tong University School of Medicine 220
Large-scale testing (Phase 3)Looking for participantsNCT05744687
What this trial is testing

Phase II/III Study of SPH4336 Combined With Letrozole vs Placebo Combined With Letrozole in First-line Treatment of Breast Cancer

Who this might be right for
Locally Advanced or Metastatic Breast Cancer
Shanghai Pharmaceuticals Holding Co., Ltd 374
Testing effectiveness (Phase 2)Ended earlyNCT00130507
What this trial is testing

Benefit of Adding Trastuzumab to Second Line Chemotherapy in Breast Cancer Patients Previously Treated With Trastuzumab

Who this might be right for
Breast Cancer
Spanish Breast Cancer Research Group 14
Not applicableWithdrawnNCT02616224
What this trial is testing

Observe Treatment Patterns and Outcomes in Patients With HER2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Breast Cancer, HER2 Positive Breast Cancer, Metastatic Breast Cancer, Locally Advanced Breast Cancer
Hoffmann-La Roche
Large-scale testing (Phase 3)UnknownNCT03500380
What this trial is testing

RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or Without Liver Metastases

Who this might be right for
Breast NeoplasmsBreast DiseasesCapecitabine+3 more
RemeGen Co., Ltd. 301
Next Page